H epatocellular carcinoma (HCC) is one of the leading causes of cancer-related death globally and is the main cause of death in patients with cirrhosis.
H epatocellular carcinoma (HCC) is one of the leading causes of cancer-related death globally and is the main cause of death in patients with cirrhosis. (1) Major risk factors include hepatitis B or C virus infection, alcohol-related cirrhosis, and nonalcoholic steatohepatitis. The management of HCC has experienced tremendous improvement during the last decades, such as the development of sorafenib, regorafenib, (2) and immune checkpoint inhibitors. (3) However, the response rate of these agents is still limited. Therefore, deep understanding of HCC pathogenesis and novel treatment approaches are urgently needed for this prevalent malignancy.
In over 90% of the cases, HCC develops within an established chronic inflammatory, fibrotic, or cirrhotic liver. As such, HCC is a typical inflammation-related cancer, in which chronic inflammation facilitates the initiation and progression of HCC. (4) Aberrant secretion of cytokines and recruitment of inflammatory cells to tumor site are the main features of tumorrelated chronic inflammation. It is well-accepted that chemokines cause direct migration of immune cells to tumor tissue and serve as pro-inflammatory mediators in shaping tumor microenvironment and promoting tumor progression. (5, 6) In this regard, we and others have shown that inflammatory myeloid cells were attracted by a group of cytokines and chemokines to the HCC microenvironment to promote disease progression and drug resistance. (7) (8) (9) (10) (11) It has been postulated that each type of tissue has distinct transcriptome profiles that need specific evaluation. (12) However, the characteristic chemokine profile of HCC that shapes its distinct microenvironment remains unknown.
To this end, we scrutinized the expression of all chemokines in HCC cell lines and tissues, identifying CCL15 as the most abundantly expressed chemokine. Notably, CCL15 recruited CCR1 + CD14
+ monocytes to tumor invasive margin, and those tumor-educated monocytes in turn suppressed antitumor immune response, promoted angiogenesis, and accelerated tumor invasion/metastasis. Blockade of CCL15-CCR1 axis reduced HCC growth and metastasis in vivo, representing a promising therapeutic approach.
Materials and Methods

Cell liNeS
Cell lines HCCLM3, MHCC97H, and MHCC97L were established in our institute. (13) SMMC-7721, Huh7, L02, and 293T were purchased from the Chinese Academy of Sciences Shanghai Branch Cell Bank (Shanghai, China). All cell lines were cultured in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY) supplemented with 10% fetal bovine serum (Gibco) and 1% penicillin/streptomycin mixture. Patient clinical data collection and postsurgical surveillance were described previously. (8) Overall survival (OS) and time to recurrence (TTR) were defined as the interval from the date of surgery to death and tumor recurrence (intrahepatic recurrence or extrahepatic metastasis), respectively. However, if recurrence did not appear or patients were still alive at the last observation point, the data were censored.
FloW CytoMetRiC aNalySiS
Flow cytometry was performed as previously described. (14) Brilliant Violet 570 anti-CD45 (Biolegend, San Diego, CA), antigen-presenting cell (APC) anti-CCR1 (Biolegend), Alexa Fluor 700 anti-CD3 (Biolegend), Alexa Fluor 700 anti-CD14 (Biolegend), PE/Cy5 anti-CD15 (Biolegend), Alexa Fluor 700 anti-CD20 (Biolegend), and PE/Cy7 anti-CD56 (Biolegend) antibodies were purchased to investigate the cells types of CCR1 + cells. 
iSolatioN oF CCR1 + CD14 + CellS
Peripheral blood mononuclear cells were isolated using Lymphoprep (Fresenius Kabi-Norge, Norway) according to the manufacturer's protocols. Briefly, 10 mL of blood was collected prior to surgery in a tube containing ethylene diamine tetraacetic acid (EDTA) anticoagulant, and then carefully layered on Lymphoprep solution. After centrifugation, the mononuclear cells were collected, washed twice with magnetic cell sorting (MACS) buffer (phosphate-buffered saline [PBS] containing 1% fetal bovine serum, 0.5% EDTA, and 0.05% gentamycin), and then resuspended in MACS buffer.
Fresh tumor tissues were obtained immediately after surgery. Tumor invasive margin tissues were minced into pieces and digested in RPMI-1640 medium (Gbicol) containing 1 mg/mL collagenase (Gbicol), 0.4 mg/mL hyaluronidase, and 1% penicillin/streptomycin mixture on a gentleMACS Octo Dissociator with Heaters machine (Miltenyi Biotec, Germany) for 1 hour. Subsequently, the cell suspension was passed through a 400-mesh sieve and centrifuged at 500 g for 10 minutes. After the supernatant was removed, the depositing cells were washed twice with PBS, resuspended in PBS, and carefully layered on Lymphoprep solution. After centrifugation, the mononuclear cells were collected, washed, and resuspended in MACS buffer. CCR1 + CD14 + cell isolation was performed on a BD FACSMelody according to the manufacturer's protocols, with a purity greater than 95%. Brilliant Violet 570 anti-CD45, APC anti-CCR1, and PE/ Cy7 anti-CD14 antibodies were used to label the CCR1 + CD14
+ cells. The sorted cells were resuspended in MACS buffer.
Details of other materials and methods used in this study are described in the Supporting Information.
StatiStiCal aNalySiS
The results were recorded as mean ± SD. SPSS 20.0 software (Chicago, IL) was used for statistical analysis. Statistical P values were analyzed by a twotailed Student t test. Kaplan-Meier analysis (log-rank test) was used to describe differences in patients' OS and TTR. Multivariate Cox proportional hazards regression analyses were performed to analyze the independent prognostic factors. P value less than 0.05 (two-sided) was considered to be statistically significant.
Results
CCl15, tHe MoSt aBuNDaNt CHeMoKiNe iN HCC, iS RegulateD By Cell iNtRiNSiC aND eXtRiNSiC FaCtoRS
To determine which chemokines were most abundant in HCC, pan-chemokine array was used to scrutinize a total of 5 HCC cell lines and 12 paired HCC tumor/normal tissues. With reference to normal liver cell line, L02, CCL15, CXCL5, and CXCL6 were the top three overexpressed chemokines in HCC cell lines; and with reference to normal liver tissues, CCL15 and CCL16 were the most overexpressed ones in HCC tumor tissues (Fig. 1A) . Then, immunostaining confirmed that CCL15 expression was high in aggressive HCC cell lines HCCLM3 and MHCC97H and was low in the less aggressive HCC cell line SMMC-7721 (Fig. 1A) . Thus, we speculated that CCL15 may have a crucial role in HCC progression, considering that CCL15 was highly expressed in both HCC cell lines and tissues, and preliminary data have indicated CCL15 as a potential biomarker for HCC. (15, 16) In HCC tissues, western blot analysis also confirmed that CCL15 was significantly upregulated in tumor tissues (75%, 12 of 16) (Fig. 1B) . Notably, serum CCL15 concentration was significantly higher in HCC patients than those in healthy controls (17.43 ± 7.10 versus 11.51 ± 4.25 ng/mL; P = 0.0003) and was even much higher in patients with aggressive tumor features like larger tumor (P < 0.001) and vascular invasion (P = 0.004) (Fig. 1C) .
Next, we explored the potential mechanisms that may lead to CCL15 upregulation in HCC. Data from the Cancer Genome Atlas (TCGA) database showed that, in tumor tissues, copy number of CCL15 gene positively correlated with mRNA expression of CCL15 (Fig. 1D) . In addition, a significantly negative correlation was observed between CCL15 DNA methylation and CCL15 expression (Fig. 1D) , and DNA demethylation agent obviously restored CCL15 expression in HCC cells (Fig. 1E ). In the HCC microenvironment, the cytokine ingredients were characterized with high levels of interleukin (IL)-6, IL-8, interferon-γ (IFN-γ), and tumor necrosis factor-α (TNF-α). (17) We therefore investigated the stimulating effects of IL-6, IL-8, IFN-γ, and TNF-α on tumor cell production of CCL15. Fig. 1F shows that in HCCLM3 and SMMC-7721 cell lines, TNF-α was the most powerful inducer of CCL15 expression, whereas IL-6 and IL-8 had no such effects. IFN-γ could also stimulate HCCLM3 cells to produce CCL15 but had no influence on SMMC-7721 cells. Collectively, these results indicate that CCL15 was one of the most abundant chemokines in HCC, which was regulated by genetic, epigenetic, and microenvironmental factors.
HigH eXpReSSioN oF CCl15 CoRRelateS WitH pooR CliNiCal outCoMe
To investigate the clinical relevance of CCL15 expression in HCC, immunohistochemistry of CCL15 was performed in tissue microarrays containing tumors and paired nontumor liver tissues from two independent cohorts of HCC patients (n = 360 and n = 253, respectively). The typical immunostaining images of CCL15 are presented in Fig. 2A , showing minimal intensity in nontumor liver and obvious upregulation in tumor tissues. Survival analysis indicated that, in the training cohort, patients in the CCL15-high group had a markedly shorter median OS and TTR (OS, 54.2 months; TTR, 52.9 months) than those in the CCL15-low group (OS, 63.2 months, P = 0.001; TTR, 67.3 months, P < 0.001) (Fig. 2B) . Similarly, in the validation cohort, patients with high CCL15 expression had a poorer prognosis (OS, 38.1 months; TTR, 32.4 months) than those with low expression (OS, 50.2 months, P < 0.001; TTR, 45.2 months, P < 0.001) (Fig. 2B) . Moreover, multivariate analysis indicated that CCL15 was the independent prognostic factor for both OS (training cohort: HR = 1.404, P = 0.035; validation cohort: HR = 1.694, P = 0.020, Supporting Table S2 ) and TTR (training cohort: HR = 1.895, P < 0.001; validation cohort: HR = 1.641, P = 0.014, Supporting Table S3) in HCC patients.
We also evaluated the relationships between CCL15 expression and tumor clinicopathologic characteristics. In the training cohort, CCL15 expression positively correlated with liver cirrhosis (P = 0.004), high level of serum alpha-fetoprotein (P < 0.001), larger tumor size (P < 0.001), presence of microvascular invasion (P = 0.045), and advanced tumor node metastasis (TNM) stage (P = 0.019) (Supporting Table S4 ). Likewise, in the validation cohort, CCL15 expression positively correlated with larger tumor size (P < 0.001) and presence of microvascular invasion (P < 0.001), poor tumor differentiation (P = 0.022), . Tumor size smaller than 5 cm (n = 37), tumor size larger than 5 cm (n = 33); no MVI (n = 39), MVI (n = 31). **P < 0.01, ***P < 0.001. (D) Correlation between CCL15 mRNA expression and CCL15 gene copy number from the TCGA database (n = 360), and correlation between CCL15 mRNA expression and CCL15 DNA methylation level from the TCGA database (n = 370). (E) CCL15 expression in SMMC7721 cells was increased on treatment of 5-Aza-CdR for 48 hours in a concentration-dependent manner. Data are presented as mean ± SD from three independent experiments. ***P < 0.001. (F) Stimulating effects of IL-6 (10 ng/mL), IL-8 (50 ng/mL), IFN-γ (50 ng/mL), and TNF-α (10 ng/mL) on tumor cell production of CCL15. Data are presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations: MVI, microvascular invasion; N, nontumor; T, tumor. and advanced TNM stage (P = 0.026) (Supporting Table S4 ). Therefore, high CCL15 expression in HCC may signify a dismal clinical outcome and tumor aggressiveness.
CCl15 pRoMoteS HCC iNVaSioN iN aN autoCRiNe MaNNeR
In HCCLM3, a line with high expression of CCL15, CCL15 was downregulated, whereas SMMC-7721, a line with low expression of CCL15, was forced to overexpress CCL15, along with respective controls (Supporting Fig. S1A,B) . We found that upregulation or downregulation of CCL15 had no effect on HCC cell proliferation in vitro (Supporting Fig. S1C,D) . However, CCL15 knockdown significantly inhibited the invasion of HCCLM3 cells, and CCL15 overexpression significantly enhanced the invasion of SMMC-7721 cells (Supporting Fig. S1E,F) . Interestingly, exogenous CCL15 could markedly promote the invasive abilities of HCCLM3-shCCL15 and SMMC-7721-pcDNA cells when compared with their respective controls (Supporting Fig. S1E,F) . Consistent with our previous study, (18) CCR1 was expressed in most HCC cell lines, especially in HCCLM3 cells (Supporting Fig. S2A ). Notably, the mRNA level of CCR1 in CCR1 + inflammatory cells was far surpassed any HCC cell lines, almost 30 times higher than that in HCCLM3 cells (Supporting Fig.  S2B ). Typical immunostaining images confirmed that CCR1 was expressed on both HCC cells and infiltrating inflammatory cells (Supporting Fig. S2C ).
CCl15 ReCRuitS CCR1
+ CD14
+ MoNoCyteS to HCC iNVaSiVe MaRgiN
Considering that CCL15 primarily and specifically bound to CCR1, we speculated that intratumoral CCL15 could recruit CCR1 + cells to tumor lesion. Immunostaining of CCR1 indicated that CCR1 were expressed primarily on infiltrating inflammatory cells, and those CCR1 + cells were predominately accumulated in HCC invasive margin (Fig. 2C) . In paraffin-embedded HCC samples (n = 120), the densities of CCR1 + inflammatory cells in invasive margin (median, 32.1 cells/field, Supporting Fig. S3A ) were significantly higher than those in nontumor liver (median, 23.2 cells/field, P < 0.001, Supporting Fig. S3A ) and in tumor center (median, 14.6 cells/ field, P < 0.001, Supporting Fig. S3A) . A high number of CCR1 + inflammatory cells in the invasive margin, rather than those in the nontumor liver and tumor center, was significantly associated with poor prognosis in HCC patients (Fig. 2D) . Multivariate analysis suggested that the density of CCR1 + inflammatory cells in invasive margin was an independent prognostic index for both OS (hazard ratio [HR] = 2.173, P = 0.010) and TTR (HR = 1.944, P = 0.013) (Supporting Table S5 ) in HCC patients. Moreover, the number of CCR1 + inflammatory cells in the invasive margin was associated with larger tumor size (P = 0.002), absence of tumor encapsulation (P = 0.026), presence of microvascular invasion (P = 0.003), and advanced TNM stage (P = 0.001) (Supporting Table S6 ). A significant positive correlation between CCL15 expression in tumor and the number of CCR1 + inflammatory cells in tumor invasive margin were observed (r = 0.384, P < 0.001) (Supporting Fig.  S3B,C) . Considering the positive correlation between CCL15 expression and CCR1
+ inflammatory cells, we also investigated the effect of combined CCL15 and CCR1 on patient outcome. The results showed that patients with simultaneously high expression of CCL15 and CCR1 + cells had the worst outcomes, whereas those with simultaneously low expression had the best survival (Supporting Fig. S3D) .
Next, in vitro chemotaxis assay showed that CCR1 + inflammatory cells were attracted in parallel with the increasing of CCL15 concentration, achieving the optimal chemotaxic concentration at 100 ng/ mL (Supporting Fig. S4A ). In contrast, the number of CCR1 + attracted inflammatory cells decreased gradually when CCR1 antagonist ( J113863, Tocris Bioscience) was added ( Supporting Fig. S4B ). These data powerfully indicate that CCL15 is an effective chemokine in recruiting CCR1
+ inflammatory cells to accumulate in the HCC microenvironment.
CCR1 + iNFlaMMatoRy CellS aRe CD14 + MoNoCyteS tHat SuppReSS aNtituMoR iMMuNity aND FaCilitate tuMoR MetaStaSiS
We next explored the biological role of invasive-margin CCR1 + inflammatory cells in HCC. Flow cytometry analysis indicated that, in the invasive margin, the main cell type of CCR1 + inflammatory cells was CD14 + monocytes (an average of 79.8%) (Fig. 3A,B) . Immunofluorescence further confirmed that CCR1 + inflammatory cells were predominately enriched in the invasive margin of HCC, most of which were CD14 + monocytes (Fig. 3C) . Compared with peripheral CCR1 + CD14 + monocytes, invasive margin-derived CCR1 + CD14 + monocytes expressed significantly higher levels of PD-L1, B7-H3, TIM-3, and CD80 (Fig. 3D) . However, no significant differences were observed in the expression of PD-L1, B7-H3, TIM-3, and CD80 in CCR1 -CD14
+ monocytes derived from peripheral blood and the HCC invasive margin (Supporting Fig. S5A ). Additionally, no significant differences were found in the expression of PD-L1, B7-H3, TIM-3, and CD80 between peripheral CCR1 -CD14
+ and CCR1 + CD14 + monocytes (Supporting Fig. S5B ).When compared with invasive-margin CCR1 -CD14 + monocytes, invasive-margin CCR1 + CD14 + monocytes expressed significantly higher levels of PD-L1, B7-H3, and CD80 (Supporting Fig. S6A ). The coculture supernatant (CS; HCC cells + invasive-margin CCR1 + CD14 + monocytes) and coculture supernatant 1 (CS1; HCC cells + invasive-margin CCR1 -CD14 + monocytes) both significantly enhanced the HCC cells' invasive ability, compared with Med (Supporting Fig. S6B ). Obviously, we observed a significantly stronger promotion of coculture supernatant with invasive-margin CCR1 + CD14 + monocytes than invasive-margin CCR1 -
CD14
+ monocytes (HCCLM3 CS and CS1, P = 0.038; SMMC-7721 CS and CS1, P = 0.003).
Then, RNA-seq analysis on 13 pairs of peripheral and invasive margin CCR1 + CD14 + monocytes further confirmed that the latter may exert tumor-promoting effects compared with the former. A total of 2090 differentially expressed genes (DEGs) were identified from the RNA-seq data based on the criteria of |log2(-fold-change)| > 1 of the comparisons and P < 0.05 (Supporting Table S7 ). Hierarchical clustering based on these DEGs obviously distinguished invasive margin from peripheral CCR1 + CD14 + monocytes (Fig. 4A) . Genes upregulated in invasive-margin CCR1 + CD14 + monocytes primarily enriched in pathways related to leukocyte activation, regulation of cytokine production, and cell migration (Fig. 4B) , whereas downregulated genes were involved in versatile pathways like metabolic process, immune response, and regulation of protein binding (Fig. 4C) . Specifically, we focused on monocyte-related pro-tumor and immune-suppressive molecules. We found that numerous chemokines were upregulated in invasive-margin CCR1 + CD14 + monocytes, such as CCL2, CCL17, CCL24 and CXCL6, which may recruit myeloid cells and regulatory T cells to HCC or directly stimulate HCC cell invasion. (8, 19, 20) (Fig. 4D) . Moreover, pro-inflammatory cytokines were also enhanced in invasive-margin CCR1 + CD14
+ monocytes, such as IL-6, IL-8, IL-10, and granulocyte-macrophage colony stimulating factor (GM-CSF) (Fig. 4E) . More importantly, co-inhibitory molecules and immune tolerogenic metabolic enzymes, including PD-L1, cytotoxic T-lymphocyte antigen 4, lymphocyte activation gene 3, TIM-3, indoleamine 2,3-dioxygenase and arginase 1, were significantly higher on invasive-margin CCR1 + CD14 + monocytes, indicating a strong suppression of antitumor immunity (21) (Fig. 4F) . Meanwhile, CD163L1, CD200R, transglutaminase 2, and vascular endothelial growth factor upregulation implied a M2 macrophage polarization and pro-angiogenic potential on tumor-margin CCR1 + CD14
+ monocytes (22) (Fig. 4F ). In addition, various kinds of matrix metalloproteinase, including matrix metalloproteinase 2 and matrix metalloproteinase 9, were significantly increased in invasive-margin CCR1 + CD14
+ monocytes that may function to facilitate tumor metastasis (Fig. 4F) + monocytes when compared with control media (Supporting Fig. S7A ). We also compared the promotion of proliferative and invasive + monocytes had no obvious effect (Supporting Fig. S7B,C) .
The promotion of proliferative and invasive abilities was also observed when HCC cells were directly + monocytes from healthy donors (data not shown).
Considering the tumor-promoting effect of CS, we compared the level of a panel of 102 cytokines in CS and HCC cell supernatant at 12 hours (Fig. 6A) . Of note, the secretion of numerous cytokines was markedly elevated in CS when compared with controls. The top-elevated cytokines shared by HCCLM3 and SMMC-7721 cells' CS were TNF-α, CCL3/ CCL4, GM-CSF, CD26, MMP-9, IL-1rα, CCL2, and IL-6 (Fig. 6B) . Notably, these cytokines were well-known for their promoting effects in tumor growth and metastasis.
The typical epithelial-to-mesenchymal transition (EMT) phenotypes, including upregulation of N-cadherin, Snail and Slug, and downregulation of E-cadherin, were observed in cocultured HCCLM3 and SMMC-7721 cells, when compared with control cells, respectively (Fig. 6C) . Morphologically, cocultured HCCLM3 and SMMC-7721 cells presented a spindle morphology, when compared with their controls (Fig.  6D) . Immunofluorescent staining further confirmed that cocultured HCC cells exhibited obviously EMT phenotypes compared with the controls (Fig. 7A,B) .
To illustrate the potential mechanisms of CCR1 + CD14 + monocytes-mediated pro-tumor Data are presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. (C) CCK8 assays showing the effects on HCC cell proliferative ability from different cell supernatants. Data are presented as mean ± SD from three independent experiments. *P < 0.05, **P < 0.01, and ***P < 0.001. Abbreviations: Med, control media; HS, HCC cell supernatant; MS, CCR1 + CD14 + monocyte supernatant.
effects, alterations of intracellular signaling pathways in HCC cells were detected. The intracellular signaling array showed that phosphorylation of STAT3 (signal transducer and activator of transcription 3) and AKT (v-akt murine thymoma viral oncogene homolog) were significantly upregulated in cocultured HCCLM3 and SMMC-7721 cells, compared with their respective controls (Fig. 7C ). In addition, elevated phosphorylation of ERK1/2 (extracellular signal-regulated kinase 1/2) and STAT1 was also observed in cocultured HCCLM3 and SMMC-7721 cells, respectively (Fig. 7C) . The results were further verified by western blot analysis. These data indicated that tumor-infiltrating CCR1 + CD14 + monocytes intrigue a burst of tumor-promoting cytokines and consequently promote HCC progression through multiple signaling pathways (Fig. 7D) .
BloCKaDe oF CCl15-CCR1 aXiS ReDuCeS HCC gRoWtH aND MetaStaSiS IN VIVO
To investigate the biological significance of CCL15-CCR1 axis in HCC growth and metastasis significantly more lung metastatic nodules (Fig. 8A,C) . Interestingly, tail vein injection of CCR1 + CD14 + monocytes significantly increased the tumor weight and lung metastasis in HCCLM3-shCtl xenografts. However, tail vein injection of CCR1 + CD14 + monocytes had limited effect on the tumor weight and lung metastasis in HCCLM3-shCCL15 xenografts (Fig. 8A,C) .
Likewise, tumor weight and lung metastatic nodules were significantly increased in SMMC-7721-CCL15 xenografts, compared with those in SMMC-7721-pcDNA xenografts (Fig. 8B,D) . Meanwhile, tail vein injection of CCR1 + CD14 + monocytes significantly promoted tumor weight and lung metastasis in the SMMC-7721-pcDNA group (Fig. 8B,D) . Although there was no significant difference in tumor weight between SMMC-7721-pcDNA and SMMC-7721-CCL15 xenografts after tail vein injection of CCR1 + CD14 + monocytes, a significant increase of lung metastasis was indeed observed in the SMMC-7721-CCL15 group (Fig. 8B,D) .
Then, immunostaining showed that HCCLM3-shCtl and SMMC-7721-CCL15 xenografts had a high density of CD31 + microvessels (Supporting Fig.  S8A,B) , consistent with our findings that CCL15 may exert crucial roles in neoangiogenesis. Moreover, HCCLM3-shCtl and SMMC-7721-CCL15 xenografts expressed higher levels of N-cadherin, Snail, Slug, and lower levels of E-cadherin when compared with their respective controls (Supporting Fig.  S8C,D) . As expected, after tail vein injection, significantly more CCR1 + CD14
+ monocytes were enriched in HCCLM3-shCtl and SMMC-7721-CCL15 xenografts than their respective controls (Supporting Fig.  S8E,F) . Taken together, these results confirmed that CCL15-CCR1 axis in HCC forested a pro-inflammatory microenvironment and led to increased metastatic potential of HCC cells.
Discussion
Accumulating evidence has emphasized the vital role of tumor microenvironment in HCC progression and metastasis. (23) In this study, we demonstrated that CCL15 was one of the most abundant chemokines in human HCC with significant prognostic value. CCL15 promoted tumor progression in an autocrine manner and more importantly recruited CCR1 + CD14 + monocytes to HCC invasive margin. In turn, tumor-educated monocytes inhibited antitumor immune response and promoted tumor metastasis. These findings revealed a complex tumor-promoting microenvironment shaped by CCL15-CCR1 axis in human HCC.
Several studies have indicated a crucial role of CCL15 in tumor progression, including HCC, lung cancer, and colorectal cancer. (24) (25) (26) (27) (28) It was reported that mothers against decapentaplegic homolog 4, bound directly to CCL15 gene promoter region to negatively regulate its expression in colorectal cancer. (24) (25) (26) Our present study indicated that genetic, epigenetic, and microenvironmental factors collectively governed CCL15 expression in HCC cells. We found that copy number gain of CCL15 positively correlated with CCL15 expression in HCC, in contrast to its DNA hypermethylation which correlated negatively. As a confirmation, DNA demethylation agent heavily increased CCL15 expression in HCC cells. The results supported the notion that intrinsic characteristics of tumor cells could regulate the local immune microenvironment. (29, 30) Similar to the findings that TNF-α stimulation could elevate CCL15 expression in human airway smooth muscle cells, (31) we found that TNF-α and IFN-γ could also promote CCL15 production in HCC cells. In HCC, it was demonstrated that activated monocytes highly expressed IFN-γ and TNF-α, whereas tumor cells hardly expressed them. (32, 33) These data indicate an intriguing positive feedback process between CCL15 and CCR1 + CD14
+ monocytes in the HCC tumor microenvironment.
In addition to directly promoting HCC cell invasion in an autocrine manner, (34) HCC secreted CCL15 to recruit abundant CCR1 + cells toward the tumor-invasive margin. Notably, most of these CCR1 + cells were CD14 + monocytes with potent anti-immune and pro-tumor function. In colorectal cancer, CCL15 was reported to recruit CCR1 + myeloid-derived suppressor cells and CCR1 + neutrophils to promote metastasis. (24) (25) (26) Meanwhile, CCL15 could also attract a small proportion of bone marrow-derived mesenchymal stem cells toward HCC. (27) Therefore, it appeared that the types of CCR1 + cells were diverse in different tumor microenvironments. Mechanistically, aberrant expression of PD-L1 was reported to reprogram monocytes toward the immune-suppressive direction. (35) (36) (37) In this study we showed that, in addition to immune checkpoint, upregulation of immune tolerogenic metabolic enzymes, inflammatory/proantigenic cytokines and matrix remodeling proteases, as well as inflammatory chemokines, may collectively foster the pro-tumor function of HCC-infiltrating CCR1 + CD14 + monocytes. In line with our results, previous studies also showed that activated monocytes in HCC stroma facilitated immune privilege and disease progression. (37) (38) (39) (40) Previous studies have reported several paracrine loops between tumor cells and tumor-associated macrophages/neutrophils leading to increased tumor progression, such as the CCL2/CCR2 loop that suppressed T-cell antitumor immunity, (41) and the CXCL1/2-S100A8/9 loop that induced chemoresistance. (42) In fact, such positive feedback should not be conceived as just a single loop in the complex tumor microenvironment. In this study, CCL15-recruited monocytes suppressed antitumor immunity through PD-L1, B7-H3, IDO, and attracting other immune suppressive cells, accelerated tumor invasion through activating STAT1/3, ERK1/2, and AKT signaling in HCC cells, and promoted angiogenesis. As such, interrupting either of these loops, such as the immune checkpoint inhibitors,
may not be sufficient to control HCC progression. Nevertheless, blocking CCL15-CCR1 axis significantly inhibited in vivo tumor growth and lung metastasis, and reduced CCR1 + CD14 + monocyte trafficking toward the tumor. These data support that the CCL15-CCR1 axis could be a promising therapeutic target for HCC patients, especially for those with simultaneously high intensity of CCL15 and monocytes, a subgroup of patients mimicking "hot tumor." (43) In conclusion, our results described a CCL15-CCR1 axis-mediated positive feedback mechanism in the tumor microenvironment that promoted HCC progression. CCR1 + CD14 + monocytes functioned as the executor in this feedback loop by bursting various pro-tumor and immune inhibitory factors. The characteristics of the CCL15-CCR1 axis in HCC strongly support its possibility as a therapeutic target. 
